الفهرس 
Introduction and Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 355 |  |  |
| | | from | 355 | | |
Abstract
The aim of this work is to evaluate the effectiveness and safety of the old the and new systemic therapies used for severe psoriasis.
It was concluded that from the point of effectiveness, no one therapy suited all the patients and the combination of more than one systemic therapeutic modality with lower doses of each produced the high percentage of good to excellent response than did a single agent.
This was followed by methotrexate, PUVA, cyclosporine A, Mycophenolate mofetil and hydroxyurea respectively and at the bottom came the certain therapy.
from the point of safety, mycophenolate mofetil was not associated with any abnormal findings. On the other hand, cyclosporine a treatment was reported to be associated with the highest percentage of abnormal laboratory findings especially that of the renal function tests. Regarding the clinical adverse effects, the GIT adverse effects were more the commonest in the PUVA, methotrexate and hydroxyurea groups, the cardiovascular adverse effects were the main adverse effects in the cyclosporine A group, the skin adverse effect were the comments in the PUVA, acitrien, mycophenolate mofetil and the combination groups while the infections were most encountered in the hydroxyurea group.
Ideally, Psoriasis treatment is initiated with therapies that possess the fewest side effects. If these are not effective, treatment moves to the next one until an appropriate therapy is found.
There is no ideal universal treatment for psoriasis and treatment has to be tailored to the individual patient’s requirements and needs and that what may be the best for one patient may not be quite so good for another and so the therapy of psoriasis will continue to be both science and art.
The choice of systemic medications used in the treatment of psoriasis is rapidly expanding and as the pathophysiology of psoriasis is more clearly defined, better more specific treatments may be developed and become available in the psoriasis treatment ladder.